Please provide your email address to receive an email when new articles are posted on . Women who developed HF following cardiotoxic breast cancer treatment had fewer comorbidities and better overall ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibition may improve CV outcomes in patients with diabetes undergoing cancer therapy. The ...

Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial We evaluated 2,808 echocardiograms in 829 breast cancer ...

Moderate drinkers who like to indulge in a glass of wine or beer with dinner have long taken comfort in the fact that most doctors believe this habit could do no harm or could even be good for your ...

MEMPHIS, TN — When researchers screened close to 2000 adults who had survived childhood cancer but had been exposed to cardiotoxic cancer-related therapy, they found "considerable," almost always ...

The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. ANT and TZB are both effective in the treatment of breast cancer but can be ...

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS. At the ASPC 2025 Congress ...

Doxorubicin (Doxo) is a widely used chemotherapeutic drug for cancer, though it can have toxic effects on the heart. A recent animal study investigated whether the cardioregulatory protein ...

Fewer than half of all women with breast cancer treated with chemotherapy are followed up with the recommended cardiac monitoring to help identify left ventricular dysfunction, according to a new, ...

Cardiac dysfunction is the leading cause of mortality among 10-year breast cancer survivors. Limited information regarding long-term risks of cardiac dysfunction ...